Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis

Martina Oriano, Andrea Gramegna, Leonardo Terranova, Giovanni Sotgiu, Imran Sulaiman, Luca Ruggiero, Laura Saderi, Benjamin Wu, James D. Chalmers, Leopoldo N. Segal, Paola Marchisio, Francesco Blasi, Stefano Aliberti
European Respiratory Journal 2020 56: 2000769; DOI: 10.1183/13993003.00769-2020
Martina Oriano
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Dept, Respiratory Unit and Adult Cystic Fibrosis Center, Milan, Italy
3Dept of Molecular Medicine, University of Pavia, Pavia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martina Oriano
Andrea Gramegna
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Dept, Respiratory Unit and Adult Cystic Fibrosis Center, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Terranova
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Dept, Respiratory Unit and Adult Cystic Fibrosis Center, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Sotgiu
4Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giovanni Sotgiu
Imran Sulaiman
5Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Imran Sulaiman
Luca Ruggiero
6Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Paediatric Highly Intensive Care Unit, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Saderi
4Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Sassari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Saderi
Benjamin Wu
5Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Chalmers
7University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leopoldo N. Segal
5Division of Pulmonary, Critical Care, and Sleep Medicine, New York University School of Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leopoldo N. Segal
Paola Marchisio
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
6Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Paediatric Highly Intensive Care Unit, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Blasi
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Dept, Respiratory Unit and Adult Cystic Fibrosis Center, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesco Blasi
Stefano Aliberti
1University of Milan, Dept of Pathophysiology and Transplantation, Milan, Italy
2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Dept, Respiratory Unit and Adult Cystic Fibrosis Center, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefano Aliberti
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Neutrophilic inflammation is a major driver of bronchiectasis pathophysiology, and neutrophil elastase activity is the most promising biomarker evaluated in sputum to date. How active neutrophil elastase correlates with the lung microbiome in bronchiectasis is still unexplored. We aimed to understand whether active neutrophil elastase is associated with low microbial diversity and distinct microbiome characteristics.

Methods An observational, cross-sectional study was conducted at the bronchiectasis programme of the Policlinico Hospital in Milan, Italy, where adults with bronchiectasis were enrolled between March 2017 and March 2019. Active neutrophil elastase was measured on sputum collected during stable state, microbiota analysed through 16S rRNA gene sequencing, molecular assessment of respiratory pathogens carried out through real-time PCR and clinical data collected.

Results Among 185 patients enrolled, decreasing α-diversity, evaluated through the Shannon entropy (ρ −0.37, p<0.00001) and Pielou's evenness (ρ −0.36, p<0.00001) and richness (ρ −0.33, p<0.00001), was significantly correlated with increasing elastase. A significant difference in median levels of Shannon entropy as detected between patients with neutrophil elastase ≥20 µg·mL−1 (median 3.82, interquartile range 2.20–4.96) versus neutrophil elastase <20 µg·mL−1 (4.88, 3.68–5.80; p<0.0001). A distinct microbiome was found in these two groups, mainly characterised by enrichment with Pseudomonas in the high-elastase group and with Streptococcus in the low-elastase group. Further confirmation of the association of Pseudomonas aeruginosa with elevated active neutrophil elastase was found based on standard culture and targeted real-time PCR.

Conclusions High levels of active neutrophil elastase are associated to low microbiome diversity and specifically to P. aeruginosa infection.

Abstract

Active neutrophil elastase correlates with low microbiota diversity and P. aeruginosa detected as relative abundance (Pseudomonas), standard culture and targeted real-time PCR in sputum samples of adult bronchiectasis patients in stable state https://bit.ly/2LUkpVq

Introduction

Bronchiectasis is a chronic respiratory disease characterised by an abnormal and permanent dilatation of the bronchi in the context of a clinical syndrome of cough, sputum production and frequent respiratory infections [1]. Neutrophilic airway inflammation is recognised as one of the major drivers of bronchiectasis pathophysiology, and has clear implications on clinical outcomes [2, 3]. Up to 80% of bronchiectasis patients enrolled across different experiences worldwide show neutrophilic airway inflammation [3–6]. Neutrophil elastase detected in sputum is a promising biomarker in bronchiectasis patients, and its activity correlates not only with disease severity, lung function and quality of life, but also with the exacerbation rate [3].

Neutrophil elastase is released from neutrophils during degranulation and formation of extracellular traps, and has antibacterial effects against respiratory pathogens [7]. Among the different inflammatory stimuli driving the release of neutrophil elastase from neutrophils, bacteria and, specifically, Gram-negative infections (e.g., Pseudomonas aeruginosa, Haemophilus influenzae and Enterobacteriaceae) are the most potent [3]. Although the association between neutrophil elastase activity (aNE) and the presence of chronic bacterial infection has been widely explored through culture-based microbiology in both bronchiectasis and other chronic respiratory diseases, a deep analysis of the association of airways microbiota and neutrophilic inflammation measured by neutrophil elastase is still unreported in bronchiectasis [3]. Multiple studies enrolling patients with asthma, COPD, idiopathic pulmonary fibrosis or cystic fibrosis demonstrated a loss of bacterial diversity in the lung compared to healthy controls [8–10]. Experiences evaluating airway microbiota did not identify differences in α-diversity between bronchiectasis patients and healthy subjects, although these results are limited by the small sample size and the large heterogeneity that characterises this disease [11–14].

Therefore, we postulated that bronchiectasis patients with elevated aNE comprised a more homogenous group characterised by a distinct microbiome with lower diversity.

Materials and methods

Study design and population

An observational cross-sectional study was carried out at the bronchiectasis programme of the respiratory department, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, between March 2017 and March 2019. Consecutive patients aged ≥18 years with clinically (daily sputum production) and radiologically (at least one lobe involvement on chest computed tomography) significant bronchiectasis were recruited during clinical stability (≥1 month from the last exacerbation and antibiotic course). Patients with cystic fibrosis or traction bronchiectasis due to pulmonary fibrosis were excluded. The study was approved by the ethical committee of the hospital, and all subjects provided written informed consent to participate.

Study procedures

Bronchiectasis patients underwent clinical, radiological, microbiological and functional evaluation. Spontaneous sputum samples were obtained and mucus plugs were isolated. DNA was extracted according to a published technique [15, 16]. Positive and negative controls were extracted along with samples. A second aliquot of mucus plug was diluted ×8 in PBS, vortexed and centrifuged at 4°C for 15 min at 3000×g. Sample supernatants were stored at −80°C. For aNE assessment, ProteaseTag Active Neutrophil Elastase Immunoassay (Proaxis, Belfast, UK) was used as per manufacturer's instructions [17].

Bacterial real-time PCR and microbiome evaluation

Bacterial DNA was amplified and quantified using real-time PCR assay for Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae [18].

High-throughput sequencing of bacterial 16S rRNA-encoding gene amplicons (V3–V4 region) was performed according to previously published studies [15, 16].

Specific descriptions of real-time PCR procedure and microbiome analysis are reported in the supplementary material.

Clinical variables

Demographics, comorbidities, disease severity, aetiology of bronchiectasis, respiratory symptoms, sputum evaluation, radiological, functional and biological characteristics in stable state were recorded, and are reported in the supplementary material.

Study groups

A priori we split patients into two groups based on the concentration of aNE (20 µg·mL−1) defined by Chalmers et al. [3] as being most associated with worse outcomes in bronchiectasis: aNE ≥20 µg·mL−1 versus aNE <20 µg·mL−1.

Statistical analysis

Variables were collected in an ad hoc electronic form. Qualitative variables were summarised with absolute and relative (percentage) frequencies, whereas quantitative variables were described using median (interquartile ranges (IQR)) values. Qualitative variables were statistically assessed using Chi-squared or Fisher exact test, when appropriate, whereas those for quantitative nonparametric variables used Mann–Whitney tests. aNE was correlated to continuous variables with Spearman correlation. A two-tailed p-value <0.05 was considered statistically significant. A univariate and multivariate linear regression analysis was carried out to assess the relationship between levels of aNE and epidemiological and microbiological variables based on β-coefficients and related 95% confidence intervals. The statistical software Stata version 15 (StataCorp, College Station, TX, USA) was used for all statistical computations.

Sample size calculation was based on the assumption of a higher level of Shannon diversity in patients with a lower aNE. We assumed a mean difference of 0.5 (means of 2.8 and 3.3 in aNE ≥20 µg·mL−1 and aNE <20 µg·mL−1, respectively) and a common standard deviation of 1.19; the estimated sample size was 180, with an α-error of 0.05 and a statistical power of 0.8.

16S rRNA gene sequences were analysed using the Quantitative Insights into Microbial Ecology (QIIME version 2.0 2019.07 release) pipeline for analysis of microbiome data [19]. Microbiome data are available in the Sequence Read Archive, accession number PRJNA605315. Code and metadata utilised for analysis are available at https://github.com/segalmicrobiomelab/bronchiectasis.neutrophil.elastase. Complete information on bioinformatic and statistical analysis are reported in the supplementary material.

Results

Study population

185 patients (74.6% females, median (IQR) age 63 (51–71) years) were enrolled during the study period. Clinical and microbiological variables are reported in table 1 according to the two study groups. Only five (2.7%) patients of our cohort showed an aNE level below the lower limit of detection. Patients in the aNE ≥20 µg·mL−1 group showed higher disease severity, with higher amount of daily sputum production, greater sputum purulence and lower forced expiratory volume in 1 s. >50% of the patients had chronic infection identified by culture, mainly due to P. aeruginosa (30.8%), methicillin-sensitive S. aureus (9.2%) and H. influenzae (8.1%). P. aeruginosa was also detected through real-time PCR in 43.2% of the cases, H. influenzae in 30.3%, S. aureus in 38.4% and S. pneumoniae in 36.2%. In terms of microbiome diversity, the median (IQR) Shannon index was 4.33 (3.06–5.60) and evenness was 0.75 (0.59–0.87). 109 (58.9%) patients had a median aNE <20 µg·mL−1, whereas 76 (41.1%) measured ≥20 µg·mL−1.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics of the study population according to the two study groups

Microbiome and neutrophil elastase activity

Positive and negative controls were sequenced along with samples. Negative control was reported to have 210 reads that were filtered out during the quality step. Positive control showed Bacillus 24%, Staphylococcus 12%, Lactobacillus 12%, Enterobacteriaceae 11%, Escherichia 11%, Salmonella 11%, Listeria 10% and Pseudomonas 9%.

Within-sample microbial diversity, evaluated through the Shannon entropy (ρ −0.37; p<0.00001), Pielou's evenness (ρ −0.36, p<0.00001) and richness (ρ −0.33; p<0.00001), was inversely correlated with values of aNE (figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Correlation between neutrophil elastase activity (aNE) and a) Shannon entropy, b) richness and c) Pielou's evenness.

Moreover, similar results in within-sample diversity are shown considering the two study groups.

A significant difference in terms of median (IQR) levels of Shannon diversity was detected between patients with aNE ≥20 µg·mL−1 (3.82, 2.20–4.96) versus aNE <20 µg·mL−1 (4.88, 3.68–5.80) (p<0.0001; supplementary figure A). A significant difference was found between patients with aNE <20 µg·mL−1 in terms of median (IQR) levels of richness (aNE ≥20 µg·mL−1 47.0 (29–70.0) versus aNE <20 µg·mL−1 65.5 (47.5–96.0); p<0.001) and evenness (aNE ≥20 µg·mL−1 0.68 (0.47–0.81) versus aNE <20 µg·mL−1 0.82 (0.68–0.8878); p<0.0001) (supplementary figure A). Similar results in Shannon diversity were obtained when patients with pulmonary ciliary dyskinesia (PCD) as well as those with primary/secondary immunodeficiency were excluded (supplementary table A). A direct correlation between aNE and Pseudomonas relative abundance was found (ρ 0.37, p<0.0001), while an inverse correlation is shown between Streptococcus and aNE levels (ρ −0.5, p<0.001). No correlation was seen between Staphylococcus and aNE, while a mild inverse correlation emerged with Haemophilus (ρ −0.18, p=0.016) (figure 2).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Correlation of neutrophil elastase activity (aNE) levels with a) Pseudomonas, b) Streptococcus, c) Haemophilus and d) Staphylococcus relative abundance.

Non-metric multidimensional scaling based on Bray–Curtis dissimilarity is shown in figure 3. Samples clustered in two separate groups according to aNE levels (PERMANOVA p=0.001). Biplot of samples (categorised according to aNE levels) and taxa (summarised at a genus level) showed that the high-aNE group co-occurred with Pseudomonas, whereas the low-aNE group co-occurred with Streptococcus, Haemophilus and Staphylococcus.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Biplot including non-metric multidimensional scaling (NMDS) on the basis of Bray–Curtis distances for groups of neutrophil elastase activity (aNE) ≥20 µg·mL−1 and aNE <20 µg·mL−1 and genera.

Further compositional analysis showed a differential enrichment between the two groups: Pseudomonas was the only genus increased in the aNE ≥20 µg·mL−1 group, while Streptococcus, Rothia, Actinomyces, Abiotrophia and Atopobium were differentially enriched among aNE <20 µg·mL−1 samples (see volcano plot in supplementary figure B).

Neutrophil elastase activity and chronic bacterial infection at standard microbiology

Chronic bacterial infection and chronic P. aeruginosa infection (defined by culture) were more prevalent in patients with aNE ≥20 µg·mL−1 (chronic bacterial infection aNE ≥20 µg·mL−1 67.1% versus aNE <20 µg·mL−1 40.2%, p<0.0001; chronic P. aeruginosa infection aNE ≥20 µg·mL−1 45.2% versus aNE <20 µg·mL−1 23.5%, p=0.003). No difference in the distribution of chronic infection by S. aureus, H. influenzae, S. pneumoniae, Achromobacter denitrificans was found between the two groups.

Neutrophil elastase activity and molecular biology

A significant correlation was found between aNE and the number of copies·mL−1 of P. aeruginosa DNA in sputum (ρ 0.42, p<0.0001). Patients with levels of aNE ≥20 µg·mL−1 present with a higher real-time PCR detection in sputum for P. aeruginosa (aNE ≥20 µg·mL−1 59.2% versus aNE <20 µg·mL−1 32.1%, p<0.0001). No difference in distribution of infection by S. aureus and S. pneumoniae was found between the two groups and no correlation was found between aNE and number of copies·mL−1 of DNA load for S. aureus and S. pneumoniae. At real-time PCR, H. influenzae was significantly more frequently detected in sputum with lower levels of aNE, while a direct significant correlation was found between aNE and the number of copies·mL−1 of H. influenzae DNA in sputum (ρ 0.24, p=0.04) (figure 4). A multivariate analysis between H. influenzae and P. aeruginosa bacterial load is presented in supplementary table B. This multiparametric analysis showed that H. influenzae did not correlate with aNE levels. P. aeruginosa is the only significant variable associated with aNE (β (95% CI) P. aeruginosa 7.8 (0.7–14.9), p=0.04; H. influenzae 5.0 (−1.2–11.3), p=0.11).

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Correlation between neutrophil elastase activity (aNE) and number of copies·mL−1 of DNA load for a) Pseudomonas aeruginosa, b) Haemophilus influenzae, c) Staphylococcus aureus and d) Streptococcus pneumoniae.

Discussion

The most important findings of the present study are 1) higher levels of aNE in sputum samples from bronchiectasis patients were correlated with a decreased microbiome diversity; 2) Pseudomonas as genus and P. aeruginosa as species, detected through both molecular biology and culture, showed the best association with high levels of aNE; and 3) in addition to the presence or absence of P. aeruginosa on both culture and molecular biology, high levels of aNE were correlated with the amount of P. aeruginosa genome copies in sputum.

As a new finding and in line with our hypothesis, we found an inverse correlation between microbiota diversity and levels of aNE in sputum (based on Shannon, richness and evenness indices). This difference in terms of microbiota diversity was additionally confirmed by the evaluation of the β-diversity, which allowed separating samples in two well-defined groups. The correlation between aNE and a reduced microbiota diversity in sputum is a novel finding in bronchiectasis patients. This is consistent with studies in cystic fibrosis, where Zemanick et al. [8] demonstrated that neutrophil elastase levels negatively correlated with microbiota diversity, and reported an association between neutrophil elastase levels and P. aeruginosa infection.

From a clinical perspective, the evaluation of aNE in sputum of bronchiectasis patients confirmed data published by Chalmers et al. [3], who underlined the correlation between aNE and both disease severity and lung function. From a microbiome perspective, the characteristics of our population were very similar to those reported in previous experiences enrolling adults with bronchiectasis. For example, Lee et al. [13] observed that the most abundant phyla among subjects with bronchiectasis are Proteobacteria and Firmicutes. Furthermore, the median levels of aNE in sputum of our patients were very similar to those reported by Chalmers et al. [3] in a Scottish population of bronchiectasis patients.

In addition, we confirmed the major role of P. aeruginosa in increasing neutrophilic inflammation in bronchiectasis [20]. In the current investigation, the role of Pseudomonas as genus and P. aeruginosa as species was evaluated not only through microbiome and culture, but also through molecular biology techniques showing a positive correlation between P. aeruginosa genome copies·mL−1 and aNE. These data support the hypothesis that P. aeruginosa appears to be the most potent bacterial stimulus of neutrophil recruitment and release of neutrophil elastase in the bronchiectasis airways. As a new finding, we also discovered that the increased aNE in patients with P. aeruginosa was strongly associated with the load of P. aeruginosa detected in sputum, opening a new perspective on the role of molecular biology in bronchiectasis. This finding is in line with recent data showing that bacterial load evaluated through standard microbiology is associated with worse quality of life and increased lung inflammation in bronchiectasis [21]. Further investigations into the role of molecular biology as an aid to define disease severity, outcomes and treatment responses are needed.

Real-time PCR data suggested that the presence of H. influenzae was associated with lower levels of aNE, although there was a mild direct correlation between genome copy number and aNE. H. influenzae is a Gram-negative bacterium and previous studies described a correlation between chronic infection with H. influenzae and higher levels of neutrophil elastase [3]. The increase observed in H. influenzae colonised samples seemed to be due to co-infection with P. aeruginosa. Multivariate analysis highlighted that P. aeruginosa seemed to be the driver of aNE levels even in presence of H. influenzae [14]. Our data suggest that the presence of a co-infection with P. aeruginosa and its burden are needed to increase levels of aNE in sputum.

With regards to the other genera, Zemanick and co-workers [8, 12] also described a correlation between Staphylococcus and Enterobacteriaceae and higher levels of neutrophil elastase in cystic fibrosis, while no association between neutrophil elastase levels and Haemophilus, Prevotella and Rothia was detected. We confirmed the increased enrichment of Streptococcus genus associated with low levels of aNE, whereas no evidence of association with Staphylococcus was found [22]. Oral commensals are frequently found in healthy sputum microbiota, replaced in disease status with pathogenic bacteria [23].

One of the possible implications of our study is that aNE levels in sputum provide significant insights into the microbial environment in the airways. Microbiota analysis for the assessment of microbial environment in lungs could be used in future clinical trials evaluating the effectiveness of neutrophil elastase inhibitors. Excess of proteases in lungs causes tissue damage and alters the remodelling process. In order to counteract this imbalance, neutrophil elastase inhibitors are currently under clinical development in bronchiectasis [24–26]. Previous and ongoing clinical trials on neutrophil elastase inhibitors were not designed considering bacterial infection with specific pathogens or the presence of active elastase in sputum. The findings presented in the current investigation suggest that presence and burden of P. aeruginosa and/or aNE levels could potentially be a useful biomarker where the impact of neutrophil elastase inhibitors could be greatest [24, 25]. Our data are consistent with those of Keir et al. [20] and indicate that while patients with chronic P. aeruginosa infection may seem to be the best candidates for neutrophil elastase inhibition, its isolation might not be enough to presume high levels of aNE in sputum. Furthermore, the load of P. aeruginosa is emerging as a determining factor for the presence of high aNE levels in sputum of bronchiectasis patients and could therefore be used as a biomarker to direct neutrophil elastase inhibition.

One of the major limitations of this study includes the use of sputum as matrix of interest, which is not completely representative of the lower airways. However, sputum sampling is noninvasive and easily accessible and would be preferable as a biomarker that can be repeated multiple times over invasive lower airway samples. Furthermore, we did not assess oral microbiota, a major contaminant of sputum. Future investigations should include oral sampling paired with sputum samples in order to dissect the topographical source of the microbial signatures identified. The monocentric design of this study might limit the generalisability in geographical areas where microbiology could be different. Moreover, viral, mycobacterial and fungal communities were not evaluated. The microbiota analysis through 16S rRNA gene sequencing constitutes a cost-effective approach, but has limited capabilities due to lack of strain level resolution and functional assessment. In addition, our study did not take into account microbiota dynamics and future investigations are needed to both confirm our data and improve our findings with a longitudinal assessment during stable state and exacerbation. Microbial functioning that may affect host immune response and aNE levels should be investigated to better explore host–pathogen interaction in bronchiectasis. In conclusion, aNE levels are inversely associated to within-sample diversity in sputum of bronchiectasis patients, and directly proportional to P. aeruginosa relative abundance and load, underling the importance of the assessment of the whole bacterial community. Considering the clinical need for treatment of bronchiectasis patients, it is helpful to understand the microbial environment in lungs, which could both serve as a future biomarker for trials on neutrophil elastase inhibitors or a novel target for personalised approaches.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-00769-2020.Supplement

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-00769-2020.Shareable

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Author contributions: Conception and design: S. Aliberti and M. Oriano; formal analysis: S. Aliberti, M. Oriano, L. Terranova, L. Ruggiero, G. Sotgiu, L. Saderi, B. Wu, I. Sulaiman and L.N. Segal; investigation: S. Aliberti, M. Oriano and A. Gramegna; resources: F. Blasi, P. Marchisio and S. Aliberti; data curation: M. Oriano, G. Sotgiu, L. Saderi, S. Aliberti, L.N. Segal, F. Blasi, P. Marchisio and J.D. Chalmers; writing (original draft preparation): S. Aliberti and M. Oriano; writing (review and editing): S. Aliberti, M. Oriano, A. Gramegna, L. Terranova, G. Sotgiu, I. Sulaiman, L. Saderi, B. Wu, J.D. Chalmers, L.N. Segal and F. Blasi; supervision: F. Blasi, S. Aliberti and P. Marchisio; project administration: S. Aliberti; funding acquisition: F. Blasi, S. Aliberti and P. Marchisio.

  • Conflict of interest: M. Oriano has nothing to disclose.

  • Conflict of interest: A. Gramegna has nothing to disclose.

  • Conflict of interest: L. Terranova has nothing to disclose.

  • Conflict of interest: G. Sotgiu has nothing to disclose.

  • Conflict of interest: I. Sulaiman has nothing to disclose.

  • Conflict of interest: L. Ruggiero has nothing to disclose.

  • Conflict of interest: L. Saderi has nothing to disclose.

  • Conflict of interest: B. Wu has nothing to disclose.

  • Conflict of interest: J.D. Chalmers reports grants and personal fees from GlaxoSmithKline, Insmed, AstraZeneca and Boehringer Ingelheim, personal fees from Zambon, grants from Gilead and Grifols, outside the submitted work.

  • Conflict of interest: L.N. Segal reports personal fees for consultancy from Beyond Air, grants from NIH, outside the submitted work.

  • Conflict of interest: P. Marchisio has nothing to disclose.

  • Conflict of interest: F. Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Insmed and Pfizer, grants from Bayer, personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon, outside the submitted work.

  • Conflict of interest: S. Aliberti reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, Chiesi and INSMED, personal fees from AstraZeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon, outside the submitted work.

  • Support statement: This work was supported by the Flight Attendant Medical Research Institute (FAMRI) (BGW), Stony Wold-Herbert Fund (BGW), T32 CA193111 (BGW), UL1TR001445 (BGW). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 19, 2020.
  • Accepted May 19, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Polverino E,
    2. Goeminne PC,
    3. McDonnell MJ, et al.
    European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629. doi:10.1183/13993003.00629-2017
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Gramegna A,
    2. Amati F,
    3. Terranova L, et al.
    Neutrophil elastase in bronchiectasis. Respir Res 2017; 18: 211. doi:10.1186/s12931-017-0691-x
    OpenUrl
  3. ↵
    1. Chalmers JD,
    2. Moffitt KL,
    3. Suarez-Cuartin G, et al.
    Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017; 195: 1384–1393. doi:10.1164/rccm.201605-1027OC
    OpenUrlCrossRef
    1. Dente FL,
    2. Bilotta M,
    3. Bartoli ML, et al.
    Neutrophilic bronchial inflammation correlates with clinical and functional findings in patients with noncystic fibrosis bronchiectasis. Mediators Inflamm 2015; 2015: 642503. doi:10.1155/2015/642503
    OpenUrlPubMed
    1. Tsikrika S,
    2. Dimakou K,
    3. Papaioannou AI, et al.
    The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 2017; 99: 281–286. doi:10.1016/j.cyto.2017.08.005
    OpenUrl
  4. ↵
    1. Shoemark A,
    2. Cant E,
    3. Carreto L, et al.
    A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J 2019; 53: 1900303. doi:10.1183/13993003.00303-2019
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Taylor SL,
    2. Rogers GB,
    3. Chen ACH, et al.
    Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann Am Thorac Soc 2015; 12: 701–707. doi:10.1513/AnnalsATS.201411-513OC
    OpenUrlCrossRef
  6. ↵
    1. Zemanick ET,
    2. Wagner BD,
    3. Robertson CE, et al.
    Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 2015; 12: 221–229. doi:10.1513/AnnalsATS.201407-310OC
    OpenUrlCrossRef
    1. Ubags NDJ,
    2. Marsland BJ
    . Mechanistic insight into the function of the microbiome in lung diseases. Eur Respir J 2017; 50: 1602467.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Sulaiman I,
    2. Wu BG,
    3. Li Y, et al.
    Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J 2018; 52: 1800810. doi:10.1183/13993003.00810-2018
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Tunney MM,
    2. Einarsson GG,
    3. Wei L, et al.
    Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187: 1118–1126. doi:10.1164/rccm.201210-1937OC
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Zemanick ET,
    2. Wagner BD,
    3. Robertson CE, et al.
    Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J 2017; 50: 1700832. doi:10.1183/13993003.00832-2017
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lee SH,
    2. Lee Y,
    3. Park JS, et al.
    Characterization of microbiota in bronchiectasis patients with different disease severities. J Clin Med 2018; 7: 429. doi:10.3390/jcm7110429
    OpenUrl
  11. ↵
    1. Rogers GB,
    2. van der Gast CJ,
    3. Cuthbertson L, et al.
    Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68: 731–737. doi:10.1136/thoraxjnl-2012-203105
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Oriano M,
    2. Terranova L,
    3. Teri A, et al.
    Comparison of different conditions for DNA extraction in sputum – a pilot study. Multidiscip Respir Med 2019; 14: 6. doi:10.4081/mrm.2019.4
    OpenUrl
  13. ↵
    1. Terranova L,
    2. Oriano M,
    3. Teri A, et al.
    How to process sputum samples and extract bacterial DNA for microbiota analysis. Int J Mol Sci 2018; 19: 3256. doi:10.3390/ijms19103256
    OpenUrl
  14. ↵
    1. Oriano M,
    2. Terranova L,
    3. Sotgiu G, et al.
    Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: a comparison among different techniques. Pulm Pharmacol Ther 2019; 59: 101856. doi:10.1016/j.pupt.2019.101856
    OpenUrl
  15. ↵
    1. Gadsby NJ,
    2. McHugh MP,
    3. Russell CD, et al.
    Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clin Microbiol Infect 2015; 21: 788–788. doi:10.1016/j.cmi.2015.05.004
    OpenUrl
  16. ↵
    1. Bolyen E,
    2. Rideout JR,
    3. Dillon MR, et al.
    QIIME 2: reproducible, interactive, scalable, and extensible microbiome data science. Nat Biotechnol 2019; 37: 852–857.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Keir HR,
    2. Fong CJ,
    3. Crichton ML, et al.
    Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. ERJ Open Res 2019; 5: 00252-2018.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Sibila O,
    2. Laserna E,
    3. Shoemark A, et al.
    Airway bacterial load and inhaled antibiotic response in bronchiectasis. Am J Respir Crit Care Med 2019; 200: 33–41. doi:10.1164/rccm.201809-1651OC
    OpenUrl
  19. ↵
    1. Budayanti NS,
    2. Suryawan K,
    3. Iswari IS, et al.
    The quality of sputum specimens as a predictor of isolated bacteria from patients with lower respiratory tract infections at a tertiary referral hospital, Denpasar, Bali-Indonesia. Front Med 2019; 6: 64. doi:10.3389/fmed.2019.00064
    OpenUrl
  20. ↵
    1. Mathieu E,
    2. Escribano-Vazquez U,
    3. Descamps D, et al.
    Paradigms of lung microbiota functions in health and disease, particularly, in asthma. Front Physiol 2018; 9: 1168. doi:10.3389/fphys.2018.01168
    OpenUrlCrossRefPubMed
  21. ↵
    1. Guarino C,
    2. Hamon Y,
    3. Croix C, et al.
    Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases. Biochem Pharmacol 2017; 131: 52–67. doi:10.1016/j.bcp.2017.02.009
    OpenUrlCrossRefPubMed
  22. ↵
    1. Watz H,
    2. Nagelschmitz J,
    3. Kirsten A, et al.
    Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther 2019; 56: 86–93.
    OpenUrl
  23. ↵
    1. Polverino E,
    2. Rosales-Mayor E,
    3. Dale GE, et al.
    The role of neutrophil elastase inhibitors in lung diseases. Chest 2017; 152: 249–262.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 4 Table of Contents
European Respiratory Journal: 56 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis
Martina Oriano, Andrea Gramegna, Leonardo Terranova, Giovanni Sotgiu, Imran Sulaiman, Luca Ruggiero, Laura Saderi, Benjamin Wu, James D. Chalmers, Leopoldo N. Segal, Paola Marchisio, Francesco Blasi, Stefano Aliberti
European Respiratory Journal Oct 2020, 56 (4) 2000769; DOI: 10.1183/13993003.00769-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis
Martina Oriano, Andrea Gramegna, Leonardo Terranova, Giovanni Sotgiu, Imran Sulaiman, Luca Ruggiero, Laura Saderi, Benjamin Wu, James D. Chalmers, Leopoldo N. Segal, Paola Marchisio, Francesco Blasi, Stefano Aliberti
European Respiratory Journal Oct 2020, 56 (4) 2000769; DOI: 10.1183/13993003.00769-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Viable virus aerosol propagation by PAP circuit leak
  • Ambulatory management of secondary spontaneous pneumothorax
  • Systematic assessment of respiratory health in illness susceptible athletes
Show more Original Articles

Bronchiectasis

  • Bronchial gene expression alterations in bronchiectasis
  • Clinical outcomes of bronchiectasis in India
  • Genome sequencing reveals underdiagnosis of PCD in bronchiectasis
Show more Bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society